Lenalidomide
(Source: Reactions Weekly)
Source: Reactions Weekly - December 1, 2023 Category: Drugs & Pharmacology Source Type: research
Ibrutinib plus rituximab and lenalidomide for primary intestinal diffuse large B-cell lymphoma relapsed after anti-CD19 CAR-T cell therapy: a case report
(Source: Annals of Hematology)
Source: Annals of Hematology - December 1, 2023 Category: Hematology Source Type: research
RWD157 Assessment of Real-World Treatment Patterns and Healthcare Resource Utilization (HCRU) in Patients with Lenalidomide-Refractory Relapsed/Refractory Multiple Myeloma (RRMM) from the US Optum Database
Characterize real-world treatment patterns and HCRU in RRMM patients receiving 1 –3 prior lines (PL) of therapy. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: L. Costa, S. Nair, X. Lin, M. O'Hara, M. Slavcev, A. Marshall, R. Potluri, R. Tyagi, H. Hashmi Source Type: research
HPR183 Evaluating the Saving Potential of Lenalidomide Before and After Transition to the Reference Price System in Finland
The exclusive selling rights of several very expensive medicines are coming to an end and they are entering to the reference price system (RPS) and towards more competitive market. One of these medicines is the blockbuster cancer medicine lenalidomide, which has been among the ten best-selling medicines in Finland in terms of medicine reimbursement expenditure. The saving potential in the reimbursement expenditure of lenalidomide was evaluated before lenalidomide entered RPS in April 2022. The accuracy of our estimate was checked after lenalidomide had remained in RPS for almost one year, in the spring 2023. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: K. Sarnola, H. Koskinen, T. Kurko Source Type: research
EE691 Economic Evaluation and Budget Impact of RVd as Induction Regimen Prior to ASCT in Patients with Newly Diagnosed Multiple Myeloma from the Perspective of the Public Health Sector in Mexico
Compare the costs effectiveness of RVd (lenalidomide, bortezomib and dexamethasone) and D-VTd (daratumumab, bortezomib, thalidomide and dexamethasone) as induction regimen prior to autologous stem cell transplantation (ASCT) and estimate the budget impact associated with the use of RVd in this indication, from the perspective of the public health sector in Mexico. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: R. Romero, V. Mena Source Type: research
EE517 Cost-Effectiveness Analysis of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Greece
Tafasitamab is indicated in combination with lenalidomide followed by tafasitamab monotherapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT). We sought to evaluate the cost-effectiveness of tafasitamab and lenalidomide combination followed by tafasitamab monotherapy versus polatuzumab vedotin, bendamustine and rituximab (Pola-BR), tisagenlecleucel, and rituximab, gemcitabine and oxaliplatin (R-GemOx) from a Greek third-party payer perspective. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: M. Karaiskou, A. Avgitidou, Z. Vostitsanou, M. Batsi, G. Bungey, T. Prawitz, B. Peter, P. Stafylas Source Type: research
EE209 Can the German Efficiency Frontier Approach Support Decision-Making Processes for Pricing New Medicines? An Application to Second-Line Interventions of Transplant-Ineligible Diffuse Large B-Cell Lymphoma
For patients with diffuse large B-cell lymphoma (DLBCL), treatment options (interventions) are limited if their disease relapses or is refractory (r/r) to first-line therapy and they are ineligible for stem cell transplantation. Innovative interventions have been recently approved by the European Medicine Agency (tafasitamab-lenalidomide, Tafa-L; polatuzumab-bendamustine-rituximab, Pola-BR) for second-line (2L) treatment addressing this unmet medical need. Further interventions, e.g., CAR-T-cell therapies, are expected to be introduced for the 2L soon, albeit at rising treatment costs. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: M.S. Kurte, A.C. Siefen, F. Jakobs, B. von Tresckow, H.C. Reinhardt, F. Kron Source Type: research
CO101 Multiple Myeloma (MM) Refractory to Lenalidomide: A Systematic Literature Review (SLR) of Randomised Controlled Trials (RCTs)
Lenalidomide is increasingly used in early lines of therapy for patients with MM. Patients treated with lenalidomide, especially in maintenance settings, often experience relapse and become refractory. RCTs in second line and beyond (2L+) feature patients with varying lenalidomide exposure resulting in variable outcomes. Evaluation of 2L+ RCTs focusing on first-line lenalidomide exposure and subsequent impact on outcomes is valuable; understanding the evidence supporting therapies and associated outcomes in 2L+ lenalidomide-refractory patients is vital. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: S. McNamara, G. Kazeem, J.A. Carter, J. Bitetti, P.F. Wang Source Type: research
CO24 Daratumumab in Combination with Lenalidomide and Dexamethasone Improves Survival in Newly Diagnosed Transplant-Ineligible Multiple Myeloma: A Parametric Network Meta-Analysis in a United Kingdom Setting
Daratumumab in combination with lenalidomide and dexamethasone (DRd) is indicated for patients with newly diagnosed transplant-ineligible multiple myeloma. Previous hazard ratio network meta-analyses (NMA) have shown DRd to be clinically superior to other treatments. Proportional hazard assumption (PHA) violations in the network, however, required the exploration of advanced NMA methods. This research aimed to conduct a parametric NMA (PNMA) to evaluate overall survival (OS) and progression-free survival (PFS) for DRd compared with relevant treatments in the United Kingdom (UK) setting. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: S. van Beekhuizen, A. Bird, A. Freitag, Z. Yuan, T. Ming Source Type: research
P25 Association between Adherence to Lenalidomide and Patient-Reported Outcomes in Patients with Multiple Myeloma: A Systematic Literature Search
Lenalidomide, a molecular-targeted agent that binds to cereblon, is active in multiple myeloma (MM), the second most common haematological malignancy. Continuous exposure is associated with efficacy; however, the impact of adherence to lenalidomide oral maintenance therapy on quality of life is unclear. We assessed the available literature to assess the relationship between adherence and patient-reported outcomes (PROs) in lenalidomide-treated MM patients. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: K. Ramasamy, M. von Lilienfeld-Toal, C. Maisel, B. Gustavsson, K. B äck, A. Glasmacher, X. Leleu Tags: Adherence to Treatment, Patients' Preferences, and Drug Use across Multiple Diseases Source Type: research
Real-world multiple myeloma risk factors and outcomes by non-Hispanic Black/African American and non-Hispanic White race/ethnicity in the United States
Haematologica. 2023 Nov 30. doi: 10.3324/haematol.2023.282788. Online ahead of print.ABSTRACTExamination of the impact of race and ethnicity on multiple myeloma (MM) outcomes has yielded inconsistent results. This retrospective, real-world (RW) study describes patient, disease, and treatment characteristics (and associations with survival outcomes) among newly diagnosed MM patients of non-Hispanic (NH) Black/African American (AA) and NH White race/ethnicity in the United States. We included patients from the nationwide Flatiron Health electronic health record-derived de-identified database who initiated first line of thera...
Source: Haematologica - November 30, 2023 Category: Hematology Authors: Tondre Buck Monique A Hartley-Brown Yvonne A Efebera Carter P Milner Jeffrey A Zonder Paul G Richardson Taylor Salinardi Megan S Rice Source Type: research
Emergence of < em > TP53 < /em > mutation during lenalidomide therapy of myelodysplastic syndrome with del(5q) and its subsequent disappearance following salvage therapy with decitabine
Haematologica. 2023 Nov 30. doi: 10.3324/haematol.2023.284547. Online ahead of print.ABSTRACTNot available.PMID:38031760 | DOI:10.3324/haematol.2023.284547 (Source: Haematologica)
Source: Haematologica - November 30, 2023 Category: Hematology Authors: Naseema Gangat Naresh Bellam Kaaren Reichard Ayalew Tefferi Source Type: research
Real-world multiple myeloma risk factors and outcomes by non-Hispanic Black/African American and non-Hispanic White race/ethnicity in the United States
Haematologica. 2023 Nov 30. doi: 10.3324/haematol.2023.282788. Online ahead of print.ABSTRACTExamination of the impact of race and ethnicity on multiple myeloma (MM) outcomes has yielded inconsistent results. This retrospective, real-world (RW) study describes patient, disease, and treatment characteristics (and associations with survival outcomes) among newly diagnosed MM patients of non-Hispanic (NH) Black/African American (AA) and NH White race/ethnicity in the United States. We included patients from the nationwide Flatiron Health electronic health record-derived de-identified database who initiated first line of thera...
Source: Haematologica - November 30, 2023 Category: Hematology Authors: Tondre Buck Monique A Hartley-Brown Yvonne A Efebera Carter P Milner Jeffrey A Zonder Paul G Richardson Taylor Salinardi Megan S Rice Source Type: research
Emergence of < em > TP53 < /em > mutation during lenalidomide therapy of myelodysplastic syndrome with del(5q) and its subsequent disappearance following salvage therapy with decitabine
Haematologica. 2023 Nov 30. doi: 10.3324/haematol.2023.284547. Online ahead of print.ABSTRACTNot available.PMID:38031760 | DOI:10.3324/haematol.2023.284547 (Source: Haematologica)
Source: Haematologica - November 30, 2023 Category: Hematology Authors: Naseema Gangat Naresh Bellam Kaaren Reichard Ayalew Tefferi Source Type: research
A Polyherbal Ashwagandha Formulation Exhibits Adjunctive Antitumor Efficacy Against U266 Myeloma Cells by Multi-Strategic Cytotoxic Effects: An Experimental Approach
Conclusion: Habb-e-asgandh formulation possess anti-tumorigenic efficacy against multiple myeloma. The adjunctive Habb-e-asgandh formulation with standard chemotherapeutic drug may prove to be a potent anti-myeloma agent in interventional therapy for Multiple myeloma if further studied in future avenues.PMID:38019228 | DOI:10.31557/APJCP.2023.24.11.3705 (Source: Asian Pacific Journal of Cancer Prevention)
Source: Asian Pacific Journal of Cancer Prevention - November 29, 2023 Category: Cancer & Oncology Authors: Shraddha Kapoor Nidhi Gupta Alpana Sharma Source Type: research
